Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with...
October 17, 2025 16:20 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both...
October 17, 2025 06:30 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to...
October 16, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms.Leveraging...
October 13, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology...
October 06, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel

Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as...
October 03, 2025 01:05 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance...
October 03, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Change in the Roche Board of Directors

Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at...
October 01, 2025 16:30 ET | Source: F. Hoffmann-La Roche Ltd

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB)...
September 30, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and...